Circulating omentin is associated with coronary artery disease in men

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 811-814

  Shibata, Rei ^a   Ouchi, Noriyuki ^a   Kikuchi, Ryosuke ^a   Takahashi, Ryotaro ^b   Takeshita, Kyosuke ^a   Kataoka, Yoshiyuki ^a   Ohashi, Koji ^a   Ikeda, Nobuo ^b   Kihara, Shinji ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Chunichi Hospital   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adipocytokine; Coronary artery disease; Omentin; Risk factors

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMENTIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CYTOKINES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GPI-LINKED PROTEINS; HUMANS; JAPAN; LECTINS; LOGISTIC MODELS; MALE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 82955184459     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.017     Document Type: Article

References (32)

1. Minino A.M., Heron M.P., Murphy S.L., Kochanek K.D. Deaths: final data for 2004. Natl Vital Stat Rep 2007, 55:1-119.
2. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2011, 121:e46-e215.
3. Nielsen S., Jensen M.D. Obesity and cardiovascular disease: is body structure a factor?. Curr Opin Lipidol 1997, 8:200-204.
4. Nakamura T., Tokunaga K., Shimomura I., et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994, 107:239-246.
5. Friedman J.M. A war on obesity, not the obese. Science 2003, 299:856-858.
6. Despres J.P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
7. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006, 3:35-42.
8. Jialal I., Devaraj S. Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol 2003, 91:200-202.
9. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
10. Lago F., Dieguez C., Gomez-Reino J., Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3:716-724.
11. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003, 14:561-566.
12. Ouchi N., Higuchi A., Ohashi K., et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010, 329:454-457.
13. Gable D.R., Hurel S.J., Humphries S.E. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006, 188:231-244.
14. Shibata R., Ouchi N., Murohara T. Adiponectin and cardiovascular disease. Circ J 2009, 73:608-614.
15. Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
16. Schaffler A., Neumeier M., Herfarth H., Furst A., Scholmerich J., Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
17. Tsuji S., Uehori J., Matsumoto M., et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001, 276:23456-23463.
18. de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
19. Moreno-Navarrete J.M., Catalan V., Ortega F., et al. Circulating omentin concentration increases after weight loss. Nutr Metab (London) 2010, 7:27.
20. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
21. Tan B.K., Adya R., Farhatullah S., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
22. Moreno-Navarrete J.M., Ortega F., Castro A., Sabater M., Ricart W., Fernandez-Real J.M. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011.
23. Liu R., Wang X., Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011.
24. Yamawaki H., Tsubaki N., Mukohda M., Okada M., Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010, 393:668-672.
25. Yamawaki H., Kuramoto J., Kameshima S., Usui T., Okada M., Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011.
26. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
27. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
28. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
29. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
30. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
31. Despres J.P. Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk. Heart 2009, 95:1118-1124.
32. Despres J.P. Excess visceral adipose tissue/ectopic fat the missing link in the obesity paradox?. J Am Coll Cardiol 2011, 57:1887-1889.